Genmab A/S (OTCMKTS:GNMSF - Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $230.86 and traded as low as $191.84. Genmab A/S shares last traded at $191.84, with a volume of 11 shares.
Genmab A/S Stock Up 1.6 %
The company has a fifty day moving average of $206.25 and a two-hundred day moving average of $229.26. The stock has a market capitalization of $13.94 billion, a price-to-earnings ratio of 20.29 and a beta of 1.04.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $5.70 earnings per share for the quarter, topping the consensus estimate of $0.46 by $5.24. Genmab A/S had a return on equity of 17.73% and a net margin of 23.49%.
Genmab A/S Company Profile
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
